The purpose of the collaborationis to quickly and widely disseminate information on the proper use of ABRYSVO in the maternal immunisation applications, providing mutually agreed upon information on appropriate use to medical institutions in Japan. Pfizer will continue to be responsible for development, manufacturing, distribution, sales, etc. as before.

ABRYSVO is the first RSV vaccine given during pregnancy as maternal immunisation in Japan, and it is expected that neutralising antibodies against RSV induced in the vaccinated mother will transfer to the fetus, thereby protecting newborns and infants after birth from RSV infection.

Through this co-promotion, Pfizer, the manufacturer and distributor of this vaccine, and ASKA Pharmaceutical, which has strengths in the field of obstetrics and gynecology, will leverage their respective expertise and networks within the healthcare facilities to further strengthen the provision of information on this new preventive approach for RSV, the maternal immunisation, and the promotion of its appropriate use.

RSV infection is one of the major causes of lower respiratory tract diseases such as bronchiolitis and pneumonia in infants, and is known to be at a particularly high risk of developing severe illness in infants shortly after birth. Through this initiative, the two companies aim to contribute to seamless infection prevention from pregnancy through to infancy.